| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/25/2002 | US20020048786 Nucleotide sequences for use in the treatment of infections, arthritis, karposi's sarcoma, allergies, asthma, nervous system and autoimmune diseases |
| 04/25/2002 | US20020048785 Novel polypeptides within the tumor necrosis factor receptor superfamily and uses therefor |
| 04/25/2002 | US20020048769 Protein-protein interactions in neurodegenerative disorders |
| 04/25/2002 | US20020048764 Human PEM as a target for birth contol and treatment of Alzheimer's disease |
| 04/25/2002 | US20020048600 Residual drug content in the device is minimized by the utilization of a flow-promoting layer between a semi-permeable wall; delivery devices having high drug loading |
| 04/25/2002 | US20020048583 Combining ex vivo an antigen and an antigen-presenting cell binding agent specific for the antigen, and administering the composition to a patient suffering from a disease associated with the antigen |
| 04/25/2002 | US20020048571 Chimeric polypeptides of serum albumin and uses related thereto |
| 04/25/2002 | US20020048271 Methods and composition for restoring conformational stability of a protein of the p53 family |
| 04/25/2002 | DE10051321A1 New 2-(4-amino-piperidin-1-yl)-2-aryl-N-(phenylalkyl)-acetamides, are potent neurokinin antagonists, useful e.g. for treating allergic, inflammatory or central nervous system diseases |
| 04/25/2002 | DE10051320A1 New 2-(4-amino-piperidin-1-yl)-2-aryl-N-(phenylalkyl)-acetamides, are neurokinin antagonists having a long duration of action, useful e.g. for treating allergic, inflammatory or central nervous system diseases |
| 04/25/2002 | CA2426604A1 Compounds with high monoamine transporter affinity |
| 04/25/2002 | CA2426592A1 Combination of statins and sorbitol dehydrogenase inhibitors |
| 04/25/2002 | CA2426487A1 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 04/25/2002 | CA2426381A1 Cell damage inhibitor |
| 04/25/2002 | CA2426371A1 Human tuberoinfundibular peptide of 39 residues |
| 04/25/2002 | CA2426271A1 Dihydropyrimidine derivatives as cysteine protease inhibitors |
| 04/25/2002 | CA2426120A1 Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders |
| 04/25/2002 | CA2426097A1 New derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication |
| 04/25/2002 | CA2425963A1 Human kinases |
| 04/25/2002 | CA2425900A1 Novel medicinal herbal composition for treating liver diseases and hiv |
| 04/25/2002 | CA2425804A1 Urotensin-ii agonists and antagonists |
| 04/25/2002 | CA2425514A1 S-adenosylmethionine and derivatives thereof for the treatment and prevention of alzheimer's disease |
| 04/25/2002 | CA2424729A1 Estrogen receptor modulators |
| 04/25/2002 | CA2424726A1 Estrogen receptor modulators |
| 04/25/2002 | CA2424345A1 Liposomal formulation of mitoxantrone |
| 04/25/2002 | CA2423792A1 Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| 04/25/2002 | CA2423789A1 Bridged piperazine derivatives |
| 04/25/2002 | CA2423073A1 Recombinant antibody fragments as autoantibody antagonists |
| 04/25/2002 | CA2422717A1 2-, 3-, 4-, or 5-substituted-n1-(benzensulfonyl)indoles and their use in therapy |
| 04/25/2002 | CA2421597A1 Cycloalkylfluorosulfonamide derivatives |
| 04/25/2002 | CA2420994A1 Method of treating stroke |
| 04/24/2002 | EP1199372A2 Polymorphisms in the human P2X7 gene |
| 04/24/2002 | EP1199074A1 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 04/24/2002 | EP1199071A2 Use of an estrogen agonist/antagonist for improving vascular health |
| 04/24/2002 | EP1199068A2 NMDA NR2B antagonists for treating depression and neurodegenerative disorders |
| 04/24/2002 | EP1199067A2 Prophylactic use of N-Methyl-D-Aspartate (NMDA) antagonists |
| 04/24/2002 | EP1198995A1 Anti-stress composition for incorporation in nutritional carriers |
| 04/24/2002 | EP1198570A1 Monomeric protein of the tgf-beta family |
| 04/24/2002 | EP1198568A1 Compositions and methods for the treatment of immune related diseases |
| 04/24/2002 | EP1198556A2 Methods for producing and preparing cells for cell therapy |
| 04/24/2002 | EP1198477A1 Prolactin-releasing peptide and method for regulating autonomic functions and treating pain |
| 04/24/2002 | EP1198463A2 Compounds for use in treatment of neurological disorders |
| 04/24/2002 | EP1198456A2 Potassium channel openers |
| 04/24/2002 | EP1198453A2 N-(indolcarbonyl-)piperazin derivatives |
| 04/24/2002 | EP1198451A2 Substituted phenoxyacetic acids |
| 04/24/2002 | EP1198246A2 Methods for preventing or attenuating pathoangiogenic conditions by using the gbs-toxin (cm101) receptor as a vaccine |
| 04/24/2002 | EP1198241A1 Novel proteins |
| 04/24/2002 | EP1198240A2 Tissue regenerating agent |
| 04/24/2002 | EP1198229A1 Therapeutic agents |
| 04/24/2002 | EP1180366A9 Neuronal death inhibitors |
| 04/24/2002 | EP1035858B1 Use of ginkgo biloba extracts for preparing a medicine |
| 04/24/2002 | EP0932407A4 Method for treating migraine pain |
| 04/24/2002 | EP0822813B1 A combination of a 5-ht uptake inhibitor with a selective 5-ht 1a antagonist |
| 04/24/2002 | EP0782568B1 Aromatic ethers derived from indols such as 5ht1-like ligands |
| 04/24/2002 | CN1346370A Polypeptides involved in immune response |
| 04/24/2002 | CN1346368A Potassium channel interactors and uses therefor |
| 04/24/2002 | CN1346364A 16-hydroxyestratrienes as selective estrogens |
| 04/24/2002 | CN1346350A Compound which inhibiti leukocyte adhesion mediated by VLA-4 |
| 04/24/2002 | CN1346349A Pyrazoelcarboxylic acid derivatives, their preparation, pharmaceutical compositions containing |
| 04/24/2002 | CN1346346A O-thiocarbamoyl-aminoalkanol copmound, their pharmaceutically acceptable salt and process for preparing the same |
| 04/24/2002 | CN1346344A Substituted 2-aminobenzamide caspase ihibitors and the use thereof |
| 04/24/2002 | CN1346343A 3-bicycloaryl-2-aminomethyl bicycloalkanes as serotonine reuptake inhibitors |
| 04/24/2002 | CN1346283A External coated chewing gum products |
| 04/24/2002 | CN1346278A Regulation of anaesthesia |
| 04/24/2002 | CN1346272A Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases |
| 04/24/2002 | CN1346266A Analgesic regimen |
| 04/24/2002 | CN1345724A Indolylpiperidine compound and preparation process and use thereof |
| 04/24/2002 | CN1083448C 1-phenyl-4-benzylpiperazines: dopamine receptor subtype specific ligands (D4) |
| 04/24/2002 | CN1083443C 吲哚衍生物 Indole derivatives |
| 04/24/2002 | CN1083431C Novel heterocyclic compounds |
| 04/24/2002 | CN1083419C Pentanoic acid derivatives, its preparation, medicinal materials having same and use thereof |
| 04/24/2002 | CN1083265C Improved pharmaceutical formulations containing ibuprofen and codeine |
| 04/24/2002 | CN1083264C Pharmaceutical compositions comprising an opiate ant agonist and calcium salts, their use for the treatment of endorphin-mediated pathlogies |
| 04/24/2002 | CN1083263C Use of melatonin for treating patients suffering from drug addiction |
| 04/24/2002 | CN1083262C Composition of L-dopa esters |
| 04/24/2002 | CN1083260C Novel pharmaceutical composition for the preparation of a stable powder containing an active principle comprising an association of acetylsalicylic acid and metoclopramide |
| 04/23/2002 | US6376675 Pyridyl-1,2,5-thiadiazole derivatives |
| 04/23/2002 | US6376673 Central nervous system disorders |
| 04/23/2002 | US6376666 2-mercaptobenzimidazole derivatives possessing pharmacological activity |
| 04/23/2002 | US6376665 Antiarthritic agents, antiinflammatory agents |
| 04/23/2002 | US6376548 Enhanced propertied pesticides |
| 04/23/2002 | US6376545 Tablet |
| 04/23/2002 | US6376540 Furan nitrone compounds |
| 04/23/2002 | US6376539 Antiischemic agents, central nervous system disorders |
| 04/23/2002 | US6376532 Neurotransmitter |
| 04/23/2002 | US6376530 A n-methylaspartic acid antagonist; nervous system disorders, analgesics |
| 04/23/2002 | US6376526 For huans, animals |
| 04/23/2002 | US6376518 Anticarcinogenic agents; side effect reduction |
| 04/23/2002 | US6376517 For treating vision loss, preventing vision degeneration, and promoting vision regeneration (?neopsis?) |
| 04/23/2002 | US6376507 NK-1 receptor antagonists for the treatment of neuronal injury and stroke |
| 04/23/2002 | US6376495 Antidiabetic piperazine derivatives, processes for their preparation and compositions containing them |
| 04/23/2002 | US6376493 Selective inhibition of phosphodiesterase iv and tumor necrosis factor; useful in treating osteoporosis, tumors, autoimmune diseases, rheumatic diseases, and asthma |
| 04/23/2002 | US6376490 Strong n-methyl-d-asparate receptor antagonists; useful in treating strokes, ischemia, and central nervous system injuries |
| 04/23/2002 | US6376489 Cyclic AMP-specific phosphodiesterase inhibitors |
| 04/23/2002 | US6376478 N-acetylated (alpha)-linked acidic dipeptidase inhibitor; blocks release of glutamte pre-synaptically for reduced toxicity |
| 04/23/2002 | US6376214 DNA encoding a novel homolog of CSBP/p38 MAP kinase |
| 04/23/2002 | US6376205 Contacting tau protein or derivative bound to solid phase with agent suspected of being modulator or inhibitor of tau-tau association and material which binds to said protein, detecting binding, wherein decrease indicates modulation |
| 04/23/2002 | CA2042934C Treatment of ocular hypertension with an ocular synergistic combination |
| 04/18/2002 | WO2002031499A1 Detection of neurodegenerative disorders |
| 04/18/2002 | WO2002031151A2 Lipocalins |